The 22-item benefit finding scale: validation and application among patients with cervical cancer in ethnic minority areas of southwestern china
| dc.contributor.author | Peng, Zhouyuan | |
| dc.contributor.author | Liu, Ke | |
| dc.contributor.author | Zhang, Yuting | |
| dc.contributor.author | Hong, Qingyu | |
| dc.contributor.author | Sun, Liyuan | |
| dc.date.accessioned | 2023-03-01T18:17:27Z | |
| dc.date.available | 2023-03-01T18:17:27Z | |
| dc.date.issued | 2022-08-04 | |
| dc.description.abstract | Recently, the Benefit Finding Scale (BFS) has been translated and culturally adapted for use in China. However, further validation of the instrument is required before it can be used in the management of patients with cervical cancer in China. In this study, we conducted the questionnaire survey and examined its properties. This methodological study was conducted at a tumor hospital located in southwestern China. Patients with cervical cancer who had been reexamined in the outpatient department of the hospital and hospitalized from June to August 2019 were selected. The item analysis, exploratory factor analysis (EFA), and reliability analysis were tested. The relationships between benefit finding and sociodemographic and disease-related variables were analyzed by ANOVA and regression models. A total of 247 patients were assessed (mean age: 48.0 ± 13.3 years). Educational level, self-perceived disease severity, and physical exercise were the predictors of benefit finding. The correlation coefficient between 22 items and their dimensions was the best. EFA analysis supported a five-factor model for structure validity. All Cronbach's alpha for the Chinese version of the BFS (BFS-C) was greater than 0.80. The results demonstrated the good reliability and validity of BFS-C. It appears to be a useful scale to assess experience of benefit finding among patients with cervical cancer in China. | en_US |
| dc.identifier.citation | Peng, Z., Liu, K., Zhang, Y., Hong, Q., & Sun, L. (2022). The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China. Contrast media & molecular imaging, 2022, 8977011. https://doi.org/10.1155/2022/8977011 | en_US |
| dc.identifier.other | DOI: 10.1155/2022/8977011 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14041/5942 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Contrast Media & Molecular Imaging | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject | Cervical Cancer | en_US |
| dc.subject | Ethnic Minority Areas | en_US |
| dc.subject | Southwestern China | en_US |
| dc.title | The 22-item benefit finding scale: validation and application among patients with cervical cancer in ethnic minority areas of southwestern china | en_US |
| dc.type | Article | en_US |